Serum levels of soluble form of Fas molecule in patients with congestive heart failure

American Journal of Cardiology

Volumn 79, Issue 12, 1997, Pages 1698-1701

  Okuyama, Masaki ^a   Yamaguchi, Seiji ^a   Nozaki, Naoki ^a   Yamaoka, Minako ^a   Shirakabe, Masanori ^a   Tomoike, Hitonobu ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; HEART DILATATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0030856469     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00228-2     Document Type: Article

References (25)

1. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233-243.
2. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas Christiane, Li-Weber Min, Richards S, Dhein J, Trauth BC, Ponsting H, Krammer PH. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem. 267:1992;10709-10715.
3. Tanaka M, Itoh H, Adachi S, Akimoto S, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 75:1994;426-433.
4. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
5. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
6. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (Anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 169:1989;1747-1756.
7. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
8. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol. 149:1992;3753-3758.
9. Cheng W, Baosheng L, Kajstura J, Peng L, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch-induced programmed myocyte cell death. J Clin Invest. 96:1995;2247-2259.
10. Narura J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
11. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med. 335:1996;1190-1196.
12. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
13. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biolog Chem. 264:1989;11974-11980.
14. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 265:1990;1531-1536.
15. Girardin E, Roux-Lombard P, Grau GE, Suter H, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentration in severe meningococcaemia. Immunology. 76:1992;20-23.
16. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
17. Vassalli P. The pathophysiology of tumor necrosis factor [review]. Annu Rev Immunol. 10:1992;411-452.
18. Clement MV, Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J Exp Med. 180:1994;557-567.
19. Okubo M, Ishida H, Kawashima R. Elevated levels of soluble Fas in systemic lupus erythematosus: comment on the article by Knipping et al. Arthritis Rheum. 39:1996;1612-1613.
20. Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB, Mann DL. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
21. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor: structure and function [review]. Trends Cell Biol. 5:1995;392-399.
22. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-a in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
23. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNFa processing in RA synovial membrane cell cultures. J Clin Invest. 97:1996;2833-2841.
24. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
25. Mounts JD, Pierson MC, Zhou T, Cheng J, Elkon KB, Hasunuma T, Nishioka K, Okumura K, Lin A, Song GG, Dale JK, Gorley M, Straus SE. Fas expression in patients with autoimmune disease. Arthritis Rheum. 38:((suppl 9)):1995;S174.